Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
Rhea-AI Summary
Elanco (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. A conference call with the investment community and media will be held the same day starting at 8:00 a.m. Eastern Standard Time. Investors, media, and the public can access a live webcast via Elanco's investor website and a replay will be available on the site shortly after the call.
Positive
- None.
Negative
- None.
News Market Reaction – ELAN
On the day this news was published, ELAN gained 2.51%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $296M to the company's valuation, bringing the market cap to $12.07B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ELAN is up 0.58% with moderate volume. Several pharma peers in its group show gains (e.g., ALKS +6.48%, PBH +2.86%, VTRS +2.68%), but none appear in the momentum scanner, so this move screens as stock-specific.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Conference participation | Positive | +3.3% | Participation in J.P. Morgan Healthcare Conference with leadership Q&A. |
| Dec 31 | Product approval | Positive | -0.6% | USDA approval for Befrena in canine dermatology market. |
| Dec 18 | Product approval | Positive | +0.1% | FDA conditional approval for Credelio Quattro-CA1 for screwworm. |
| Dec 09 | Investor Day targets | Positive | -5.8% | Three-year plan with growth, leverage and cost-savings goals. |
| Nov 26 | Governance/partnership | Neutral | -0.2% | Elanco executive appointed as Neurizon board observer. |
Recent news has often been strategically positive, but price reactions have been mixed, with notable divergences on major strategic updates and product approvals.
Over the last few months, Elanco has combined strategic communication with pipeline execution. An Investor Day on Dec 9, 2025 outlined targets for organic growth, adjusted EBITDA and EPS expansion, and at least $1B free cash flow from 2026–2028, but the stock fell 5.81%. Regulatory wins followed, including FDA conditional approval for Credelio Quattro on Dec 18, 2025 and USDA approval for Befrena in an estimated $1.3B market, with muted price impact. Today’s earnings-date confirmation fits a consistent pattern of regular investor communications alongside product and strategy milestones.
Market Pulse Summary
This announcement sets the timetable for Elanco’s fourth quarter and full year 2025 financial results on February 24, 2026, with a conference call at 8:00 a.m. EST. It continues a pattern of regular earnings-date confirmations, for which past similar releases saw an average move of 3.49%. Investors following the story may focus on how forthcoming results align with prior Investor Day targets and recent product approvals, using the call to assess execution and outlook for 2026 and beyond.
AI-generated analysis. Not financial advice.
The conference call will begin at 8:00 a.m. Eastern Standard Time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
Investor Contact: Tiffany Kanaga (765) 740-0314 tiffany.kanaga@elancoah.com
Media Contact: Colleen Parr Dekker (317) 989-7011 colleen.dekker@elancoah.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-confirms-date-and-conference-call-for-fourth-quarter-and-full-year-2025-financial-results-announcement-302667237.html
SOURCE Elanco Animal Health
FAQ
When will Elanco (ELAN) release Q4 and full-year 2025 results?
What time is the Elanco (ELAN) earnings conference call on February 24, 2026?
How can I listen to Elanco (ELAN) Q4 2025 results conference call?
Will a replay of Elanco's (ELAN) February 24, 2026 call be available?
Who is the intended audience for Elanco's (ELAN) February 24, 2026 call?
Where is the Elanco (ELAN) webcast link located for the February 24, 2026 event?
